Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen

Pediatr Infect Dis J. 2010 Apr;29(4):376-9. doi: 10.1097/INF.0b013e3181c81fd4.

Abstract

Recent updates of the guidelines on the prevention of human immunodeficiency virus mother-to-child transmission have shortened the neonatal zidovudine prophylactic regimens from 6 to 4 weeks. We present a prospective observational study in a large cohort of mother-infant pairs and report that the 4-week regimen allows an earlier recovery of the anemia in these otherwise healthy infants.

MeSH terms

  • Adult
  • Anemia* / chemically induced
  • Anemia* / epidemiology
  • Anti-HIV Agents* / adverse effects
  • Anti-HIV Agents* / therapeutic use
  • Chemoprevention*
  • Drug Administration Schedule
  • Female
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / virology
  • Reverse Transcriptase Inhibitors* / adverse effects
  • Reverse Transcriptase Inhibitors* / therapeutic use
  • Zidovudine* / administration & dosage
  • Zidovudine* / adverse effects
  • Zidovudine* / therapeutic use

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Zidovudine